Paroxetine
- Generic Name
- Paroxetine
- Brand Names
- Paxil, Pexeva
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20FNO3
- CAS Number
- 61869-08-7
- Unique Ingredient Identifier
- 41VRH5220H
- Background
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this...
- Indication
Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the tr...
- Associated Conditions
- Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
- Associated Therapies
- -
Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD)
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 65
- Registration Number
- NCT00700999
- Locations
- 🇺🇸
Jesse Brown VA Medical Center Community-Based Outpatient Clinic Lake Side Divison, Chicago, IL, Chicago, Illinois, United States
🇺🇸VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States
🇺🇸Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States
A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
- First Posted Date
- 2008-05-14
- Last Posted Date
- 2021-01-27
- Target Recruit Count
- 321
- Registration Number
- NCT00677352
- Locations
- 🇯🇵
Pfizer Investigational Site, Minato-ku, Japan
Effects of Paxil CR on Neural Circuits in Posttraumatic Stress Disorder (PTSD)
- Conditions
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Emory University
- Target Recruit Count
- 40
- Registration Number
- NCT00672776
A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
- Conditions
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2010-06-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 750
- Registration Number
- NCT00666757
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brown Deer, Wisconsin, United States
Neural Correlates of Early Intervention for Posttraumatic Stress Disorder (PTSD)
- Conditions
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2012-07-11
- Target Recruit Count
- 160
- Registration Number
- NCT00665678
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 286
- Registration Number
- NCT00658762
- Locations
- 🇭🇺
Pfizer Investigational Site, Budapest, Hungary
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 360
- Registration Number
- NCT00658372
- Locations
- 🇨🇳
Pfizer Investigational Site, Tainan, Taiwan
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 501
- Registration Number
- NCT00658008
- Locations
- 🇷🇺
Pfizer Investigational Site, Khotkovo, Moscow region, Russian Federation
Early Intervention for Post Traumatic Stress Disorder (PTSD)
- Conditions
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00641173
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 825
- Registration Number
- NCT00629551
- Locations
- 🇿🇦
Sanofi-Aventis Administrative Office, Midrand, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.